Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. sits in the top decile of US sponsors by registered trial count (#238 of 15,742 sponsors by registered trial count).
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: 102 sponsored US clinical trials, none currently recruiting.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. sponsors 102 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 83 completed. 38 of these trials are in Phase 3-4 (later-stage) and 62 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.
Top-decile sponsor footprint
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ranks in the top decile of sponsors by registered trial count (#238 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
83 of 102 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
102 total, page 1 of 3
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
NCT01495910
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers
NCT01454622
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers
NCT01518712
A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants
NCT01442545
A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
NCT01428284
A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
NCT01395927
A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus
NCT01381887
A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants
NCT01450982
The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women
NCT01535820
A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers
NCT01173549
A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers
NCT01202734
A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function
NCT01186588
A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers
NCT01159821
A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet
NCT01900587
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects
NCT02019485
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants
NCT01981278
JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study
NCT01105780
A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
NCT01094262
A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain
NCT01060254
Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction
NCT01063855
A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus
NCT01128985
Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent
NCT01081821
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
NCT01063868
A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy
NCT01041859
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin
NCT01054118
Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)
NCT00992589
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
NCT00993018
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
NCT01050582
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
NCT00973141
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)
NCT00964990
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
NCT00973024
A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma
NCT00946569
A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00880217
A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants
NCT02103985
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus
NCT00871507
A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder
NCT01094249
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
NCT00821600
A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
NCT00676728
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
NCT00809965
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
NCT00796120
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
NCT00786838
A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
NCT00662675
A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers
NCT01101646
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
NCT00698451
A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)
NCT01787357
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
NCT01177163
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
NCT00650806
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
NCT00642278
To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia
NCT00589693
A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function
NCT01759576
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 29 |
| Phase 3 | 32 |
| Phase 4 | 6 |
Therapeutic Areas
How the Johnson & Johnson Pharmaceutical Research & Development, L.L.C. early-phase archive is shaped
102 indexed studies, none listed as recruiting (0% open); 83 completed (81%).
Phase mix: 38 late (III/IV) vs 62 early (I/II) (early-phase heavy).
Top condition: Healthy (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: archived-pipeline peers nationwide
Peers matched on 102 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 102 archived trials
- Butler Hospital · 103 trials · 9% recruiting
- Spaulding Rehabilitation Hospital · 101 trials · 19% recruiting
- Boston University Charles River Campus · 104 trials · 22% recruiting
- Kessler Foundation · 104 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Johnson & Johnson Pharmaceutical Research & Development, L.L.C. page
102 registered trials is a research-attention snapshot, not an endorsement of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. or any single study.
- None of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition Johnson & Johnson Pharmaceutical Research & Development, L.L.C. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline card: 102 registered trials from official public datasets.Report a data error.